- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.
Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.
Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.
Latest from The University of Texas MD Anderson Cancer Center
Future Avenues of Research in Advanced NSCLC
October 20, 2025
Video
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.
Eye-Catching Data From the 2025 World Conference on Lung Cancer
October 20, 2025
Video
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.
Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC
October 17, 2025
Article
Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.
Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC
October 15, 2025
Video
Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.
Key Areas of Ongoing Research in MDS
October 15, 2025
Video
Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.
Navigating Second-Line Treatment Decisions in Lower-Risk MDS
October 15, 2025
Video
Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.
Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy
October 13, 2025
Video
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.
5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC
October 13, 2025
Video
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.
ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology
October 09, 2025
Article
Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.
Managing Immune-Related AEs in NSCLC
October 07, 2025
Article
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.
How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology
October 07, 2025
Article
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.
Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD
October 06, 2025
Podcast
Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.
Treatment Decision-Making and Sequencing Factors in Advanced Non–Small Cell Lung Cancer
September 29, 2025
Article
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.
MD Anderson and Phoenix SENOLYTIX Announce Strategic Cross-Licensing Agreement to Enhance Inducible Switch Technologies for Cell and Gene Therapies
September 19, 2025
Article
The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.
MD Anderson and Nature to Co-Host Conference on the Tumor Ecosystem
September 15, 2025
Article
Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.
Dr Mouabbi on Data From the CompassHER2 pCR Trial in HER2+ Breast Cancer
September 09, 2025
Video
Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.
Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez
September 08, 2025
Video
Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Dr Issa on Testing for NPM1 or KMT2A Alterations in AML
September 06, 2025
Video
Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.
Dr Loghavi on SOC Frontline Testing Approaches in MDS
September 05, 2025
Video
Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.